RX-10045 (synthetic resolvin analogue) on the signs and symptoms of dry eye
Dry Eye Syndrome
Enrolment: 232 · Results not recorded
Loading the evidence…
Drug · compound_search 'resolvin D2' returned 0 ChEMBL records, so resolved=false. Closest ChEMBL family member is RESOLVIN E1, CHEMBL1742483 (max_phase 1, synonym RX-10001), a DIFFERENT specialised pro-resolving mediator, deliberately NOT recorded as an identity match. No human trial administers resolvin D2 itself: NCT06356844 and NCT03095157 give precursor lipid or resolvin supplements, NCT00799552 is the RX-10045 synthetic analogue, and the two resolvin D1 studies measure it as a biomarker rather than administering it.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Dry Eye Syndrome
Enrolment: 232 · Results not recorded
Low Back Pain · Inflammatory Response · Lumbar Disc Herniation
Enrolment: 30 · Results not recorded
Persistent Post Surgical Pain
Enrolment: 80 · Results not recorded
Periodontitis
Enrolment: 26 · Results not recorded
Psoriasis
Enrolment: 30 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Full-thickness scald burn over 30% of total body surface area (dorsum immersed in boiling water for 12 s) with 40 mL/kg saline resuscitation, followed by a secondary endotoxin insult of 2 mg/kg lipopolysaccharide (Escherichia coli 0111:B4) intravenously at day 10 post burn
Resolvin D2 significantly reduced renal tubular cast formation and ballooning degeneration and hepatic necrosis and oedematous change, and prevented deterioration of blood chemistry after burn plus endotoxin (blood urea nitrogen 26.4 plus or minus 2.1 versus 36.0 plus or minus 9.3 mg/dL, p<=0.001;…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.